JRCT ID: jRCT1030240242
Registered date:30/07/2024
Survey of disease burden among patients with pulmonary sarcoidosis.
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Pulmonary sarcoidosis |
| Date of first enrollment | 30/07/2024 |
| Target sample size | 800 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Disease burden of survey participants assessed by the following questionnaires - KSQ (King's Sarcoidosis Questionnaire) - FAS (Fatigue Assessment Scale) - SFNSL (Small Fiber Neuropathy Screening List) |
|---|---|
| Secondary Outcome | Expectations for routine clinical care |
Key inclusion & exclusion criteria
| Age minimum | >= 18age old |
|---|---|
| Age maximum | Not applicable |
| Gender | |
| Include criteria | (1) Patients who are members of the sarcoidosis patient association "Sarcoidosis Tomonokai" as of July 2024 (2) Patients who have a history of pulmonary sarcoidosis (3) Patients who fully understood the consent document and gave their own voluntary consent to participate in this study (4) Patients who returned the questionnaire to the survey company (5) Patients aged 18 years or older at the time of obtaining consent |
| Exclude criteria | none |
Related Information
| Primary Sponsor | Yokota Maki |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Kyorin Pharmaceutical Co., Ltd., |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Mutsumi Kanakubo |
| Address | Yotsuya Medical bldg. 5F, No 20, Samoncho, Shinjuku-ku, Tokyo, 160-0017 JAPAN Tokyo Japan 160-0017 |
| Telephone | +81-3-6368-4833 |
| mutsumi.kanakubo@mb.kyorin-pharm.co.jp | |
| Affiliation | Kyorin Pharmaceutical Co., Ltd., |
| Scientific contact | |
| Name | Maki Yokota |
| Address | Yotsuya Medical bldg. 5F, No 20, Samoncho, Shinjuku-ku, Tokyo, 160-0017 JAPAN Tokyo Japan 160-0017 |
| Telephone | +81-3-6368-4833 |
| maki.yokota@mb.kyorin-pharm.co.jp | |
| Affiliation | Kyorin Pharmaceutical Co., Ltd., |